(Q64294550)

English

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control

No description defined

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control (English)

0 references

0 references

0 references

author name string

Manash Pratim Baruah

1

0 references

B M Makkar

2

0 references

Vikrant B Ghatnatti

3

0 references

Kaushik Mandal

4

0 references

language of work or name

0 references

Indian Journal of Endocrinology and Metabolism

0 references

23

0 references

1

0 references

140-149

0 references

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infection and diabetes: the case for glucose control

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal Na(+)-glucose cotransporters

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Older women with diabetes have a higher risk of falls: a prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower Genital Tract Infections in Diabetic Women.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type 2 diabetes mellitus: what is the optimal treatment regimen?

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes and obesity: the twin epidemics

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increasing expenditure on health care incurred by diabetic subjects in a developing country: a study from India

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of oxidative stress in diabetic bone disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 mediates glucose reabsorption in the early proximal tubule.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel insights into the relationship between diabetes and osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin: more than just another oral glucose-lowering agent?

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucose handling by the kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biology of human sodium glucose transporters

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FRAX underestimates fracture risk in patients with diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone, sweet bone--osteoporotic fractures in diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT-2 inhibitors in development for type 2 diabetes treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of comfort and discomfort in insulin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type 2 diabetes and bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin: a review on efficacy, clinical effectiveness and safety.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes and change in bone mineral density at the hip, calcaneus, spine, and radius in older women

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary tract infections in patients with diabetes treated with dapagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abstracts of the 49th Annual Meeting of the EASD

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypoglycaemic events in patients with type 2 diabetes in the United Kingdom: associations with patient-reported outcomes and self-reported HbA1c

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The costs of treating long-term diabetic complications in a developing country: a study from India.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT inhibitors in management of diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipragliflozin: first global approval

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of overweight and obesity among school children and adolescents in Chennai

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Possible adverse effects of SGLT2 inhibitors on bone

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin lowers plasma glucose concentration and improves β-cell function

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SGLT2 Inhibitors May Predispose to Ketoacidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular safety of anti-diabetic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

8. Pharmacologic Approaches to Glycemic Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018.

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/31016169

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4103/IJEM.IJEM_160_17

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64294550&oldid=2085493027"